A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands

CONCLUSIONS: Implementing Oncotype DX testing in this population can prevent unnecessary overtreatment, reducing clinical and economic burden on the patient and Dutch healthcare system.PMID:38436289 | DOI:10.1080/13696998.2024.2324612

Source: Journal of Medical Economics - March 4, 2024 Category: Health Management Authors: Martijn J H G Simons Peter M Machielsen Jelle A Spoorendonk Tim Ignacio Pieter B Drost Tim Jacobs Felix E deJongh Source Type: research